Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Novartis
Novartis
Spinal Muscular Atrophy: Four trials to watch over the next 12 months
Clinical Trials Arena
Fri, 08/11/23 - 11:39 am
clinical trials
spinal muscular atrophy
Scholar Rock
apitegromab
Novartis
Zolgensma
Spinraza
clenbuterol
Novartis prepares for FDA submission for its chronic hives treatment
Clinical Trials Arena
Wed, 08/9/23 - 10:15 am
Novartis
remibrutinib
chronic hives
FDA
Novartis sickle cell drug’s approval formally revoked by EU regulators
BioPharma Dive
Sun, 08/6/23 - 09:27 pm
Novartis
Adakveo
sickle cell disease
Europe
EMA
Biosimilar makers split strategies in bid to take on top-selling Humira
BioPharma Dive
Thu, 07/27/23 - 10:25 am
biosimilars
Humira
AbbVie
rebates
drug pricing
Amgen
Celltrion
Novartis
Boehringer Ingelheim
Biocon
Fresenius
Sandoz
Organon
Coherus
Scratching the surface of the urticaria pipeline
EP Vantage
Thu, 07/20/23 - 10:00 am
chronic urticaria
Sanofi
Dupixent
Regeneron
Novartis
Roche
Xolair
Allakos
AstraZeneca
Celldex Therapeutics
Novartis raises drug sales forecast, plans new stock buybacks
BioPharma Dive
Tue, 07/18/23 - 10:23 pm
Novartis
Novartis axes secretive obesity program after high-risk, high-reward bet fails
Fierce Biotech
Tue, 07/18/23 - 11:41 am
Novartis
obesity
pancreatic cancer
Novartis buys a preclinical biotech and its RNA drug technology
BioPharma Dive
Mon, 07/17/23 - 07:07 pm
Novartis
DTxPharma
siRNA
M&A
Novartis retreats from TIGIT, handing $300M candidate back to BeiGene
Fierce Biotech
Tue, 07/11/23 - 10:22 am
Novartis
anti-TIGIT
BeiGene
FDA approves label update of Novartis’ Leqvio to treat high LDL-C
Pharmaceutical Business Review
Tue, 07/11/23 - 10:20 am
Novartis
Leqvio
inclisiran
LDL-C
Novartis to appeal district court ruling on heart drug patent
BioPharma Dive
Mon, 07/10/23 - 09:28 pm
Novartis
Entresto
patents
legal
Biopharma buyouts bounce back
EP Vantage
Wed, 07/5/23 - 10:17 am
M&A
Amgen
Astellas
Eli Lilly
GSK
Horizon Therapeutics
Merck
Novartis
Pfizer
Seagen
Bausch + Lomb to acquire Xiidra, ‘front of eye’ assets from Novartis
Healio
Fri, 06/30/23 - 10:10 am
Bausch + Lomb
M&A
Novartis
Xiidra
dry eye disease
Ex-Novartis NASH drug clears clinical test, fueling Boston's pursuit of Akero, 89bio
Fierce Biotech
Wed, 06/21/23 - 10:51 am
Boston Pharmaceuticals
NASH
Novartis
Akero Therapeutics
89Bio
BOS-580
CAR-T beyond cancer? Novartis and others say yes
EP Vantage
Mon, 06/19/23 - 10:19 am
CAR-T
Novartis
Cabaletta Bio
Cartesian Therapeutics
Bristol Myers Squibb
Gracell
Yake Biotechnology
Sandoz targets barriers to biosimilar accessibility with latest initiative
Pharmaceutical Technology
Thu, 06/15/23 - 07:00 pm
Sandoz
Novartis
patient access
biosimilars
Biopharma Confronts a Rising Tide of Ransomware Attacks
BioSpace
Wed, 06/14/23 - 10:11 am
cyberattacks
cybersecurity
ransomware
Eisai
Sun Pharma
Novartis
AstraZeneca
Merck
Biotech M&A is picking back up - here are the latest deals
BioPharma Dive
Tue, 06/13/23 - 11:37 am
Novartis
Chinook Therapeutics
Paratek
Sobi
CTI BioPharma
Astellas
Iveric Bio
Assertio Holdings
Spectrum Pharmaceuticals
Merck
Prometheus Biosciences
Pfizer
Seagen
Sanofi
Provention Bio
Sun Pharma
Concert Pharmaceuticals
BioNTech
InstaDeep
AstraXeneca
CinCor Pharma
Ipsen
Albireo
Chiesi
Amryt
Moderna Therapeutics
OriCiro Genomics
Hope springs for April inhibition
EP Vantage
Tue, 06/13/23 - 10:27 am
Novartis
Chinook Therapeutics
April inhibition
M&A
Vera Therapeutics
Otsuka
RemeGen
Alpine Immune Sciences
Akso Biopharmaceutical
Aurinia Pharmaceuticals
Novartis to acquire kidney disease biotech Chinook for up to $3.5B
BioPharma Dive
Mon, 06/12/23 - 10:24 am
Novartis
Chinook Therapeutics
M&A
kidney disease
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »